Fresenius

ALSAD Medical is Category Winner in Tech Rocketship Award Europe

Retrieved on: 
Wednesday, March 24, 2021

The application is suitable to be inserted into health and care plans of public or private providers.

Key Points: 
  • The application is suitable to be inserted into health and care plans of public or private providers.
  • ALSAD Medical was established in 2019, as the digital health startup of Netis Informatics, a technology support company focusing on healthcare.
  • The startup collaborated with global medical provider Fresenius Medical Care, Semmelweis Medical University (Budapest) and the Associtation of Hungarian Dietitians to develop its AI-supported digital health application for people living with chronic conditions.
  • ALSAD Medical is now entering the UK and the DACH market seeking local partnerships for regional content and pilots with local health providers.

Fresenius Kabi Introduces First-Ever Generic for Foscavir® (Foscarnet Sodium) Injection

Retrieved on: 
Monday, March 15, 2021

Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.

Key Points: 
  • Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.
  • View the full release here: https://www.businesswire.com/news/home/20210315005083/en/
    Fresenius Kabi has launched the first generic for Foscavir (Foscarnet Sodium Injection).
  • Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
  • To learn more about Fresenius Kabi, including its expanding U.S. centers for pharmaceutical research, manufacturing and distribution, please visit www.fresenius-kabi.com/us .

Fresenius Medical Care Asia Pacific Continues to Forge Organization-Wide Inclusion and Diversity

Retrieved on: 
Monday, March 8, 2021

This initiative is part of the global Inclusion & Diversity efforts from Fresenius Medical Care.

Key Points: 
  • This initiative is part of the global Inclusion & Diversity efforts from Fresenius Medical Care.
  • Fresenius Medical Care is committed to serving all its patients across the globe with the same level of care and devotion to their health and wellbeing.
  • This accelerates innovation, fosters employee satisfaction, and in turn drives financial outcomes, said Harry de Wit, CEO & President of Fresenius Medical Care Asia Pacific.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

eGenesis Announces $125 Million Series C Financing

Retrieved on: 
Tuesday, March 2, 2021

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful completion of a $125 million Series C financing.

Key Points: 
  • CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful completion of a $125 million Series C financing.
  • Existing investors including Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, and Alta Partners participated.
  • In conjunction with the closing of the financing, Isaac Ciechanover, MD, from Polaris Partners, and Mark Pruzanski, MD, Founder and former Chief Executive Officer of Intercept Pharmaceuticals, joined the eGenesis Board of Directors.
  • With this financing we are now well positioned to address two of the greatest disease burdens in the U.S. and global healthcare systems.

Fresenius Medical Care North America's Products Division Earns J.D. Power Certification for Customer Service

Retrieved on: 
Wednesday, February 24, 2021

This certification is the first of its kind for a dialysis company and recognizes an "outstanding customer service experience."

Key Points: 
  • This certification is the first of its kind for a dialysis company and recognizes an "outstanding customer service experience."
  • "It is especially rewarding to earn this certification after our customer service team delivered such essential service to providers on the frontlines of the pandemic."
  • The Renal Therapies Group Customer Service team assists home patients and dialysis facilities throughout the United States in ordering dialysis supplies.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

DGAP-News: Fresenius Medical Care AG & Co. KGaA published form 20-F for the fiscal year 2020

Retrieved on: 
Wednesday, February 24, 2021

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Annual Results

Key Points: 
  • DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Annual Results
    Fresenius Medical Care AG & Co. KGaA published form 20-F for the fiscal year 2020
    The issuer is solely responsible for the content of this announcement.
  • The company also published a Facts & Figures 2020 website at factsandfigures.fmc-ag.com to provide an overview of the key financial figures for the fiscal year 2020.
  • Through its network of 4,092 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 346,553 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

DGAP-News: Fresenius Medical Care AG & Co. KGaA achieves 2020 targets, expects significant COVID-19 impact in 2021 and confirms 2025 outlook

Retrieved on: 
Tuesday, February 23, 2021

In 2020, Fresenius Medical Care provided more than 14% of its dialysis treatments in the U.S. in a home setting.

Key Points: 
  • In 2020, Fresenius Medical Care provided more than 14% of its dialysis treatments in the U.S. in a home setting.
  • This additionally affects the utilization of Fresenius Medical Care's clinic network and thereby limits the ability to mitigate fixed cost and wage inflation.
  • Fresenius Medical Care confirms its 2025 targets that are based on the Company's mid-term strategy.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Global Acute Kidney Injury Treatment Market to Thrive on Technological Progress and High Prevalence of Chronic Diseases: TMR

Retrieved on: 
Monday, February 8, 2021

The global acute kidney injury treatment market is estimated to register growth at ~7%CAGR.

Key Points: 
  • The global acute kidney injury treatment market is estimated to register growth at ~7%CAGR.
  • In the global acute kidney injury treatment market, North America is estimated to emerge as one of the leading regions.
  • Acute Kidney Injury Treatment Market: Key Driving Factors
    Increased government funding on research and development activities in the healthcare sector is expected to boost growth of the acute kidney injury treatment market in Asia Pacific.
  • Acute Kidney Injury Treatment Market: Key Market Participants
    Some of the prominent industry players comprise Fresenius Medical Care AG & Co.

Global Acute Kidney Injury Treatment Market to Thrive on Technological Progress and High Prevalence of Chronic Diseases: TMR

Retrieved on: 
Monday, February 8, 2021

All these developments are estimated to work in favor of the global acute kidney injury treatment market in the years to come.

Key Points: 
  • All these developments are estimated to work in favor of the global acute kidney injury treatment market in the years to come.
  • In the global acute kidney injury treatment market, North America is estimated to emerge as one of the leading regions.
  • Acute Kidney Injury Treatment Market: Key Driving Factors
    Increased government funding on research and development activities in the healthcare sector is expected to boost growth of the acute kidney injury treatment market in Asia Pacific.
  • Acute Kidney Injury Treatment Market: Key Market Participants
    Some of the prominent industry players comprise Fresenius Medical Care AG & Co.

Cove Capital Acquires Fresenius Medical Care Dialysis Facility in New Orleans

Retrieved on: 
Thursday, February 4, 2021

LOS ANGELES, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cove Capital Investments, LLC (Cove Capital) and its affiliates are pleased to announce the acquisition of the Fresenius Medical Care dialysis facility located at 704 Belle Terre Blvd., LaPlace, Louisiana 70068 (the Property).

Key Points: 
  • LOS ANGELES, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cove Capital Investments, LLC (Cove Capital) and its affiliates are pleased to announce the acquisition of the Fresenius Medical Care dialysis facility located at 704 Belle Terre Blvd., LaPlace, Louisiana 70068 (the Property).
  • Specifically, the Property constitutes the single asset in Cove Capitals latest medical net-lease investment offering: Cove LaPlace Dialysis 26 DST, a regulation D, Rule 506c private placement.
  • As Cove Capital continues to grow, the company remains unrelenting in its dedication to providing 1031 investors with an assortment of quality net-leased properties with what we believe to be strong and enduring tenants, including tenants in the medical industry such as Fresenius Medical Care.
  • Accordingly, the Property, and its accompanying offering, represent the latest endeavor of Cove Capital into the medical net-lease offering space and serve to grow the ever-expanding line of DST offerings Cove Capital offers to investors.